Next-Gen Peptide Therapy in ASD

🧬 New Scientific Publication Alert! 🧠

We are proud to share our latest peer-reviewed article published in the American Journal of Biomedical Science & Research:

Peptide Neuromodulation in Autism Spectrum Disorder: Targeting Neuroinflammation, Mitochondrial Dysfunction, and Synaptic Plasticity
By Prof. Dr. Mike K.S. Chan, Prof. Dr. Michelle B.F. Wong, Krista Casazza, Ian Jenkins, Jonathan R.T. Lakey

📅 Published: May 26, 2025 | Vol. 27(2) | DOI: 10.34297/AJBSR.2025.27.003532

💡 About the Article:
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition with no FDA-approved treatments targeting its core biological mechanisms. This review explores the promising role of therapeutic peptides in modulating the underlying neurobiology of ASD.

📌 Key Highlights:

✔️ Peptides can cross the blood-brain barrier and target neuroinflammation, synaptic plasticity, and mitochondrial dysfunction
✔️ Mitochondria-derived peptides (MDPs) like Humanin, MOTS-c, and SHLP2 enhance neuronal survival, reduce oxidative stress, and modulate immune responses
✔️ Nano Organo Peptides (NOPs) and Mitochondrial Organelle (MO) Peptides represent next-gen therapies for metabolic restoration, neuroimmune modulation, and synaptic repair
✔️ Clinical studies on peptides like Oxytocin, VIP, Melatonin show early promise in improving social behaviors, sleep, and reducing neuroinflammation in ASD
✔️ Peptide therapies may bridge neurobiology with precision therapeutics, offering a path toward true disease-modifying interventions for ASD

WATCH THE REEL
https://youtube.com/shorts/vO3T9U6ij4E

📖 Learn more about the publication here:
🔗 https://european-wellness.eu/publications/peptide-neuromodulation-in-autism/

📖 Read the full publication here:
🔗 https://biomedgrid.com/pdf/AJBSR.MS.ID.003532.pdf

📖 More publications here:
🔗 https://european-wellness.eu/publications/